Tong Ren Tang Technologies 2025 Annual Report: Key Financials, Developments, and Investor Takeaways

Tong Ren Tang Technologies Co. Ltd. (TRT Technologies) has released its audited 2025 Annual Report, providing a comprehensive overview of its financial performance, business operations, risk management, and shareholder matters for the year ended 31 December 2025. Below is a detailed breakdown of the most significant disclosures and developments that could be relevant for investors and may have an impact on the company’s share price.

1. Financial Performance and Business Review

• Total Income: The Group recorded total income of RMB 6,483.88 million in 2025, down from RMB 7,259.64 million in 2024, representing a year-on-year decrease of approximately 10.7%.
• Core Revenue Streams:
  • Sales of Chinese medicine products in Mainland China contributed RMB 5,226.15 million (80.60% of total income), down from RMB 5,897.50 million (81.24%) in 2024.
  • Sales outside Mainland China were RMB 1,193.87 million (18.42%), down from RMB 1,297.70 million (17.87%) in 2024.
  • Advertising services and other services combined contributed less than 1% of total income.
• Net Profit: Profit for the year attributable to owners is RMB 384.38 million, up from RMB 301.01 million in 2024, indicating margin improvement despite top-line contraction.
• Dividend: The Board proposed a final dividend of RMB 0.18 per share (including tax), totaling RMB 230.54 million, subject to shareholder approval at the AGM (expected distribution by 11 August 2026).
• Distributable Reserves: As of 31 December 2025, reserves available for distribution stand at RMB 3,289.79 million, up from RMB 3,174.84 million.
• Gearing Ratio: The Group has reduced its gearing ratio to 18.0% (from 22.2% in 2024), reflecting a stronger capital structure with total borrowings at RMB 1,844.73 million and total equity at RMB 10,264.71 million.

2. Shareholder and Corporate Structure Matters

• Share Capital: No change in share capital during the year. The company continues to meet the minimum 25% public float requirement as per the Hong Kong Stock Exchange Listing Rules.
• Dividend Taxation: Non-resident enterprise shareholders (excluding those via Shenzhen-Hong Kong Stock Connect) are subject to a 10% withholding tax on dividends.
• No Waiver Arrangements: No arrangements for waiver of dividends by any shareholders.
• No Equity-Linked Agreements: No equity-linked agreements, options, or similar instruments outstanding or entered into during the reporting period.
• Directors’ Interests: No directors or chief executives had any share or debenture interests in the company or its associates.
• Management Contracts: No management contracts for the company or any substantial part of the business.

3. Risk Management and Corporate Governance

• Major Risks Identified: The Group highlights policy risk and operational risk as key exposures.
  • Policy risk: Potential changes in pharmaceutical regulations and industry policies may impact quality management and operational procedures.
  • Operational risk: Increased costs and uncertainties from safe production management, and risks associated with production safety and quality control.
• Risk Mitigation: Proactive rectification action plans for production safety, comprehensive review and update of quality management in response to regulatory changes, and ongoing refinement of risk management systems.
• Internal Controls: No material weaknesses or failures in internal controls were identified during 2025. ESG risks are included in ongoing risk assessments.

4. Transactions and Related Party Disclosures

• Connected Transactions: All continuing connected transactions during 2025 were:
  • Approved by the Board.
  • Conducted on normal commercial terms and in accordance with the relevant agreements.
  • Did not exceed set annual caps as per regulatory announcements.
• Auditor Review: The independent auditor found no discrepancies or unapproved transactions in their review of connected transactions.

5. Other Noteworthy Developments

• Cash Donations: The Group made cash donations of RMB 705,000 in 2025 (up from RMB 100,000 in 2024).
• No Significant Disputes: No significant disputes with suppliers or customers reported during the year.
• Articles of Association Amended: In response to regulatory changes, the Articles of Association were amended and approved at shareholder meetings in August 2025.
• No Significant Events Post-Year-End: No material events requiring disclosure or adjustments occurred after 31 December 2025.

6. Shareholder Rights and Communication

• Shareholders can request general meetings and submit proposals if holding more than 10% or 1% respectively of voting shares.
• The company maintains open communication channels, including meetings, circulars, reports, and web disclosures.
• The dividend distribution policy prioritizes stable and sustainable returns, with decisions based on profitability, cash flow, financial position, and future development needs.

7. Potential Price-Sensitive Issues

• Revenue Decline: The drop in total income by over 10% year-on-year is significant and could be a concern for investors, even though net profit improved due to margin management.
• Dividend Consistency: The maintenance of the dividend at RMB 0.18 per share despite lower revenue may be seen as a sign of management confidence, but sustainability could be questioned if top-line pressures persist.
• Regulatory Risks: Ongoing regulatory changes and the company’s need to continually revise quality management systems could create operational uncertainty.
• Improved Gearing and Capital Structure: The reduction in gearing ratio enhances financial stability, which may be viewed positively by the market.

Conclusion

Tong Ren Tang Technologies’ 2025 Annual Report reveals a year of resilience, with improved profitability and capital structure despite revenue contraction. The company’s proactive risk management, stable dividend policy, and compliance with corporate governance rules provide confidence, but investors should monitor top-line growth trends and regulatory developments closely. The company’s robust distributable reserves and strong balance sheet position it well for future challenges, but persistent revenue declines could weigh on future dividend prospects and share price performance if not addressed.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The information is based on the company’s published 2025 Annual Report and may be subject to change.

View TONG REN TANG Historical chart here